VOICED : Reino Unido primer país que aprueba píldora contra el covid-19 de Merck

The UK has approved Molnupiravir, an oral COVID-19 treatment by Merck, marking the first global approval of an antiviral that can be taken at home. This approval is significant for vulnerable and immunocompromised individuals. The drug is authorized for those with mild to moderate COVID-19 and at least one risk factor for severe disease. Molnupiravir serves a dual purpose: preventing severe symptoms in infected individuals and preventing disease development in close contacts. Clinical trials indicate a 50% reduction in hospitalization when administered shortly after a positive test.

Which country was the first to approve Molnupiravir for home use?

• Canada

• United Kingdom

• United States

• Australia

What is the expected impact of Molnupiravir approval according to the British government?

• Increase in COVID-19 cases

• No significant impact

• Higher costs for healthcare

• Improved treatment for vulnerable groups

For whom is Molnupiravir authorized?

• People without any symptoms

• Anyone with COVID-19

• Those with mild to moderate COVID-19 and risk factors

• Only children

What is one of the potential uses of Molnupiravir?

• To replace vaccines

• To cure COVID-19 completely

• To prevent severe symptoms in infected individuals

• To increase the spread of the virus

By what percentage can Molnupiravir reduce the chances of hospitalization if taken soon after a positive test?

• 25%

• 50%

• 100%

• 75%